ArticleBiomaterials research2025
Evaluation of Hepatic Progenitor and Hepatocyte-Like Cell Differentiation Using Machine Learning Analysis-Assisted Surface-Enhanced Raman Spectroscopy.
Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Construction of liver organoid models by hepatobiliary differentiation from human induced pluripotent stem cells: state of the art, challenges and improving strategies.Stem cell research & therapy · 2026Review
- An artificial intelligence optimized hepatic differentiation unveils NR5A2 and AP-1 transcriptional regulation in hepatic maturation.The Journal of biological chemistry · 2026Article
- Harnessing mesenchymal stromal cells for liver disease therapy: from mechanistic discoveries to clinical breakthroughs.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Technology has been developed to monitor the differentiation process of human mesenchymal stem cells (hMSCs) into hepatocyte-like cells (HLCs) and hepatic progenitor cells (HPCs). These cell lineages, differentiated from MSCs, are ethically unproblematic and are gaining attention as promising cell-based therapies for treating various liver injuries. High-sensitivity, label-free, real-time monitoring technologies integrated with artificial intelligence have been used to evaluate and optimize cell differentiation for enhancing the efficiency of cell therapy delivery. Using an Au-ZnO nanorod array-based surface-enhanced Raman scattering (SERS) sensing chip, cell differentiation from hMSCs to HPCs and HLCs was nondestructively monitored through spectral analysis of cell secretions. Principal component extraction was employed to reduce variables, followed by discriminant analysis (DA). The application of principal component-linear discriminant analysis (PC-LDA), an artificial intelligence algorithm, to spectral data enabled clear grouping of hMSCs, HPCs, and HLCs, with monitoring accuracies of 96.3%, 98.8%, and 98.8%, respectively. Spectral changes observed during the differentiation from hMSCs to HPCs and from HPCs to HLCs over several days demonstrated the effectiveness of SERS combined with machine learning algorithm analysis for differentiation monitoring. This approach enabled real-time, nondestructive observation of cell differentiation with minimal sample labeling and preprocessing, making it useful for sensing differentiation validation and stability. The machine learning- and nanostructure-based SERS evaluation system was applied to the differentiation of ethically sourced MSCs and demonstrated substantial potential for clinical applicability through the use of patient-derived samples.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.